AwesomeCapital: Pasithea Positive Safety Review in ongoing Phase 1 Trial of Cancer Candidate

Wednesday, February 5, 2025

Pasithea Positive Safety Review in ongoing Phase 1 Trial of Cancer Candidate

SRC recommended that the trial escalate to the next dose level of 22mg capsule
No dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations

https://www.globenewswire.com/news-release/2025/02/05/3021033/0/en/Pasithea-Therapeutics-Announces-Positive-Safety-Review-Committee-SRC-Recommendation-from-its-ongoing-Phase-1-Clinical-Trial-of-PAS-004-in-Advanced-Cancer.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)